Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Passes Above Fifty Day Moving Average of $71.20

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $71.20 and traded as high as $74.07. Alnylam Pharmaceuticals shares last traded at $73.46, with a volume of 9,911 shares traded.

ALNY has been the topic of several recent analyst reports. Morgan Stanley increased their target price on Zynga and gave the stock an “overweight” rating in a research report on Thursday, May 2nd. Svb Leerink reduced their target price on Zogenix from $60.00 to $48.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 9th. Chardan Capital reiterated a “buy” rating and set a $150.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, April 9th. Zacks Investment Research downgraded Haynes International from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. Finally, Leerink Swann increased their target price on Alnylam Pharmaceuticals to $90.00 and gave the stock a “market perform” rating in a research report on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $127.44.

The company has a market cap of $7.72 billion, a price-to-earnings ratio of -9.81 and a beta of 2.50. The company has a quick ratio of 9.12, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. The firm’s fifty day moving average price is $71.20.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($1.73) EPS for the quarter, beating the consensus estimate of ($2.20) by $0.47. The business had revenue of $33.29 million for the quarter, compared to the consensus estimate of $21.60 million. Alnylam Pharmaceuticals had a negative return on equity of 55.33% and a negative net margin of 929.51%. The company’s revenue was up 52.0% on a year-over-year basis. During the same period last year, the business posted ($1.22) EPS. As a group, equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -8.45 earnings per share for the current year.

In related news, CEO John Maraganore sold 49,457 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $70.00, for a total transaction of $3,461,990.00. Following the sale, the chief executive officer now directly owns 239,450 shares in the company, valued at approximately $16,761,500. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 3.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. FMR LLC grew its stake in Alnylam Pharmaceuticals by 5.2% during the 1st quarter. FMR LLC now owns 15,945,666 shares of the biopharmaceutical company’s stock valued at $1,490,122,000 after purchasing an additional 791,113 shares in the last quarter. BlackRock Inc. grew its stake in Alnylam Pharmaceuticals by 4.6% during the 1st quarter. BlackRock Inc. now owns 6,428,127 shares of the biopharmaceutical company’s stock valued at $600,707,000 after purchasing an additional 282,322 shares in the last quarter. Baillie Gifford & Co. grew its stake in Alnylam Pharmaceuticals by 19.8% during the 1st quarter. Baillie Gifford & Co. now owns 5,684,504 shares of the biopharmaceutical company’s stock valued at $531,217,000 after purchasing an additional 937,654 shares in the last quarter. Norges Bank acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $94,228,000. Finally, First Trust Advisors LP grew its stake in Alnylam Pharmaceuticals by 1.2% during the 1st quarter. First Trust Advisors LP now owns 1,192,495 shares of the biopharmaceutical company’s stock valued at $111,439,000 after purchasing an additional 14,439 shares in the last quarter. Hedge funds and other institutional investors own 89.78% of the company’s stock.

Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Recommended Story: What is a capital gains distribution?

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.